FMCQF - IPO Update: PainReform Readies U.S. IPO Plan
Quick Take
PainReform (PRFX) intends to raise $23 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing a reformulated pain relief medication for post-operative pain reduction.
PRFX management has performed well to extend ropivacaine’s treatment envelope from six hours to up to 72 hours without disruptive changes to the operative process, providing patients with a reduced post-operative pain profile.
For life science investors with a patient hold time frame, the IPO is worth a close look.
Note: PRFX is a